The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.
ASJC Scopus subject areas
- Obstetrics and Gynaecology